Vineela Kasireddy, MD
Hematology & Oncology · Jefferson City, MONPI 1003256645
Payments from drug & device makers
Across 93 payments — averaging $55.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mirati Therapeutics, Inc.$3K
- Bristol Myers Squibb$171
- Genentech USA, Inc.$168
- Histosonics, Inc.$150
- Merck$122
- Pfizer$96
- plus $1K from 30 others
What the payments were for
- Food & beverage$1,75299%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mirati Therapeutics, Inc. | 1 | $3,386 |
| Bristol Myers Squibb | 10 | $171 |
| Genentech USA, Inc. | 9 | $168 |
| Histosonics, Inc. | 1 | $150 |
| Merck | 7 | $122 |
| Pfizer | 6 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $79 |
| AbbVie | 3 | $72 |
| Sanofi | 4 | $65 |
| E.r. Squibb & Sons, L.L.C. | 4 | $60 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $59 |
| Daiichi Sankyo Inc. | 3 | $55 |
| Novartis | 3 | $52 |
| Gilead(2 entities) | 3 | $42 |
| Puma Biotechnology, Inc. | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| Organon | 2 | $38 |
| Bayer | 1 | $38 |
| Amgen | 2 | $36 |
| EMD Serono, Inc. | 2 | $34 |
| Karyopharm Therapeutics Inc. | 2 | $32 |
| Eisai Inc. | 2 | $31 |
| Seagen Inc. | 2 | $31 |
| Foundation Medicine, Inc. | 2 | $30 |
| Array Biopharma Inc | 2 | $30 |
| Astellas Pharma US Inc | 2 | $27 |
| Rigel Pharmaceuticals, Inc. | 1 | $22 |
| Incyte Corporation | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Servier Pharmaceuticals LLC | 1 | $17 |
| GSK | 1 | $16 |
| Adaptive Biotechnologies Corporation | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Beigene USA, Inc. | 1 | $14 |
| Genmab U.S., Inc. | 1 | $14 |
| Blueprint Medicines Corporation | 1 | $13 |
How this compares
$5,149 in reported general payments places this provider in the 55th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 19 | $280,872 |
| ImbruvicaIbrutinib | 12 | $211,265 |
| XareltoRivaroxaban | 20 | $18,189 |
| EliquisApixaban | 21 | $14,315 |
| Anagrelide Hcl | 17 | $2,601 |
| Letrozole | 78 | $1,949 |
| Ondansetron Hcl | 57 | $1,702 |
| Anastrozole | 88 | $1,633 |
| Tamoxifen Citrate | 67 | $1,551 |
| Dexamethasone | 26 | $969 |
| Hydroxyurea | 31 | $751 |
| Levofloxacin | 17 | $596 |
| Potassium Chloride | 34 | $588 |
| Prochlorperazine Maleate | 43 | $524 |
| Pantoprazole Sodium | 14 | $256 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio | $18 | $280,87219 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $59 | $211,26512 claims |
| PfizerEliquis | $96 | $14,31521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Jefferson City
- Shadi HaddadinJefferson City$129K
- Ali KhojastehJefferson City$29K
- Stephanie GraffKansas City$6.2M
- Suman KambhampatiKansas City$4.9M
- Geoffrey UySaint Louis$4.1M
- Jaswinder SinghKansas City$3.9M
- Mark FeslerSaint Louis$2M
- James MosleyCape Girardeau$1.7M
- Shahzad RazaKansas City$1.7M
- Gerhard HildebrandtColumbia$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.